Other News To Note

 Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., said the FDA granted orphan designation to two of its cancer drugs, MORAb-004 in soft-tissue sarcoma and MORAb-066 in pancreatic cancer. Orphan designation will guarantee seven years of marketing exclusivity upon approval. MORAb-004, a humanized monoclonal antibody to endosialin/tumor endothelial marker-1, is in a Phase I study, while MORAb-066, a humanized monoclonal antibody to tissue factor, is in preclinical testing.